Median Technologies · EURONEXT:ALMDT
Median Technologies — Annual Conference MidCap Partners 2020
26 slides from Median Technologies's conference presentation, Sep 9, 2020
Slide 1: Median Technologies: The Imaging Phenomics Company
Median Technologies The Imaging Phenomics Company® Fredrik Brag, CEO Fredrik.brag@mediantechnologies.com
Slide 2: Median's Executive Team
Median’s Executive Team Fredrik Brag Bernard Reymann Yan Liu Nozha Boujemaa Nicolas Dano Robin Zhang Sophie Campagno CEO Chief Financial Officer Chief Medical Officer Chief Science and Chief Operating Officer General Manager Chief of Administration, & Co-founder Innovation Officer iCRO of China, iCR
Slide 3: Company's Shareholding Structure
Company’s Shareholding Structure Publicly held, listed on Euronext Growth Paris, ISIN: FR0011049824, Ticker: ALMDT 7.2% 33.1% Shareholding structure as of June 19, 2020 3 Annual Conference MidCap Partners | Paris, France | September 9th, 2020
Slide 4: Innovation Is in Our DNA
Innovation Is in Our DNA Our Mission: Leading AI-based next generation precision medicine company. Our People: As of September 2020, 130+ We focus on helping conquer cancer and employees worldwide (EU, US and China), other diseases through routine imaging tests 30% working in Research and Developmen
Slide 5: Solutions for Disease Diagnosis & Monitoring
Solutions for Disease Diagnosis & Monitoring We are transforming the science of medical imaging iCRO: Imaging solutions and Advanced services for oncology trials, analytics based on the iSee® imaging DRUG DEVELOPMENT platform Improve and optimize Imaging the assessment of new Technology drugs in cli
Slide 6: A Strong Business Activity for the First Half of 2020
A Strong Business Activity for the First Half of 2020 (unaudited figures) Revenue Order backlog • First-half revenue up 47.9% to €5.9 million, • Order backlog to €53.6 million as of June 30th, compared with €4.0 million in H1 2019 2020, • 7 consecutive quarters of revenue growth • up 40% compared wi
Slide 7: iCRO Business
iCRO Business Solutions and Services for Image Management in Clinical Trials 7 Annual Conference MidCap Partners | Paris, France | September 9th, 2020
Slide 8: Imaging CRO Solutions and Services
Imaging CRO Solutions and Services Bringing more meaning to image data: iSee® • Image analysis and data management • Limits variability and increases reproducibility platform by automatically identifying, quantifying, and tracking lesions across all time points • Extracts more data from an image tha
Slide 9: Imaging CRO Solutions and Services
Imaging CRO Solutions and Services Bringing more meaning to image data: iSee® 9 Annual Conference MidCap Partners | Paris, France | September 9th, 2020
Slide 10: Experience by Phase
Experience by Phase 122 studies (As of August 20, 2020) 28 Phase I trials Including 13 trials with Immunotherapy 122 studies also means: • 40+ clients in the US and Europe, 4 Phase I/II trials Top 10 including 1 Top 3 [1] 15 Including 9 trials with Immunotherapy • 10+ clients in China, including the
Slide 11: iCRO opportunities
iCRO opportunities Landscape • The global contract research organization (CRO) services market size was valued at USD 38bn in 2018 and is projected to reach USD 91bn by 2026 [1] • The largest market is in oncology • Competitive imaging CRO landscape: fragmented competition with 3 major players: Bioc
Slide 12: iBiopsy®
iBiopsy® Unlocking the development of precision & predictive medicine through AI-based imaging biomarkers 12 Annual Conference MidCap Partners | Paris, France | September 9th, 2020
Slide 13: iBiopsy®: Multidimensional, Integrated AI Approach
iBiopsy® : Multidimensional, Integrated AI Approach Look Beyond What You See™️: Lesion-agnostic paradigm • Comprehensive digital image signatures extraction Whole-Organ Analysis using proprietary whole-organ analysis applied to multiple organs to describe and identify new generations of non-invasive
Slide 14: iBiopsy® Platform - Strategy & Product Development Pipeline
iBiopsy® Platform - Strategy & Product Development Pipeline The iBiopsy® platform leverages Median’s expertise and capabilities in: – Imaging technology – AI and data science – Clinical development – Regulatory and reimbursement • Partnership with Assistance Publique-Hôpitaux de Paris (AP-HP) one of
Slide 15: iBiopsy® Is a Paradigm Shift in Medical Image Analysis
iBiopsy® Is a Paradigm Shift in Medical Image Analysis Novel Multimodal AI Analysis for Finer Patient Stratification ML & AI Advanced Techno Analytics Cloud Solutions Extraction Prediction Classification Matching patients with best treatments in predictive and precision medicine Imaging Signatures L
Slide 16: iBiopsy®
iBiopsy® Biopsy Liquid Biopsy iBiopsy® Non-invasive procedure No No Yes Patient risk High Low Low Standardized and cost-effective procedure No No Yes Standard of care for every stage of cancer, No No Yes screening, diagnosis, and monitoring Detection of DNA mutation Yes Yes No Overall phenotypic rep
Slide 17: Initial Clinical Development Plans
Initial Clinical Development Plans The Pheno IDX Portfolio CDP Biomarker Indication Market First result application announcements Drug Development Patient Care (small cohorts) NASH Screening NAFLD Patient recruitment Early detection of Late 2020 – Diagnosis biomarker for clinical trial advanced form
Slide 18: First Results: HCC Recurrence Prediction in Resected Patients
First Results: HCC Recurrence Prediction in Resected Patients Performance Comparison for Significant Fibrosis (F ≥ 3) – Cohort: 94 patients Non-invasive Biopsy Liquid Biopsy Imaging Transient Multiparametric iBiopsy® iBiopsy® Metavir Score Fib-4 FibroTest Elastography Elastography MRI (training) (va
Slide 19: First Results: iBiopsy® Extracts CD8+ Signature
First Results: iBiopsy® Extracts CD8+ Signature and Better Predicts Immune Microenvironment than Traditional Radiomics Traditional Radiomics1 iBiopsy® Image pre- Automated organ segmentation/no tumor Tumor manual segmentation processing segmentation Region of interest Tumor and peripheral ring Whole
Slide 20: Payer coverage and reimbursement
Payer coverage and reimbursement We can help payers reduce diagnostic and treatment costs while improving clinical outcome We believe our products offer significant health economic values in the following ways: • Reduce the need for a repeat invasive biopsy. Biopsies are not representative of the wh
Slide 21: Some Precision Medicine Comparables
Some Precision Medicine Comparables Data-driven patient profiling – Liquid Image Intent of use Biomarker Biopsy Machine learning + Data Library + biopsy biopsy CBIR CANCER - Therapy selection, early detection and recurrence Blood NO YES NO No AI, No search engine monitoring CANCER - Early detection
Slide 22: Our Strategy
Our Strategy Clinical development Business, partnerships and regulatory pathway • We will invest in our own clinical studies and • Leverage our iBiopsy® platform to expand our product develop strategic relationship with portfolio biopharmaceutical companies and luminary health institutions worldwide
Slide 23: iBiopsy® Value Drivers: a Four-pillar Approach
iBiopsy® Value Drivers: a Four-pillar Approach CLINICAL VALIDATION REGULATORY • Established strategic partnerships with KOLs • At least 2 FDA approved products (Pheno IDX) and major clinical centers for data access and • Reimbursement codes in place with strong clinical expertise revenue ramp up tre
Slide 24: Take Away Messages
Take Away Messages 24 Annual Conference MidCap Partners | Paris, France | September 9th, 2020
Slide 25: 2020 and Beyond
2020 and Beyond iCRO • Major potential for growth in a very dynamic market • Very strong technology differentiators for clinical trials: iSee® • Strong position in the fast-growing global market iBiopsy® • Very strong push for precision medicine and non-invasive biomarkers from patients, regulatory
Slide 26: Our Core Values
Our Core Values Leading innovation with purpose Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases. Committing to quality in all we do Be dedicated to quality in everything we do. Quality begins with us and we are committed to it. Sup
Median Technologies — Annual Conference MidCap Partners 2020 on 6ix